



# SIGHTSoHO

strengthening overSIGHT through training and networking on  
Substances of Human Origin

## Week 1 - Required and Additional reading



Funded by  
the European Union

This document was produced under the EU4Health Programme under a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this document are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this document. Neither the Commission/Executive Agency nor any person acting on the Commission's/Executive Agency's behalf may be held responsible for the use which may be made of the information contained therein.

## Week 1 - EU LEGAL PROVISIONS

27/01/25 - 31/01/25

Tutors and External experts involved: J. Kurz, S. Pupella

| REQUIRED READING                  |   | SELECTED PARTS  |
|-----------------------------------|---|---|
| <b>EU LEGAL ACTS</b>              |   |   |
| 1. SoHO Regulation (EU) 2024/1938 | Regulation (EU) 2024/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC | ALL   |
| 2. DIRECTIVE 2001/83/EC           | Community code relating to medicinal products for human use   | Article 1.3, 1.10, 3.6, 83, 109, 110<br>Annex Part II 1 3.2.1.b, Annex Part III 1.1 |
| 3. DIRECTIVE 2002/98/EC           | Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC   | Article 5, 4, 8, 9,10,11,12,13,14,15,<br>ANNEX IV                                   |
| 4. DIRECTIVE 2004/23/EC           | Setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells   | Recital 14, Article 2.c, 6, 7, 10.2,<br>10.3,11, 15, 16, 17, 18, 20, 24             |
| 5. DIRECTIVE 2004/33/EC           | Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components  | Article 4 ANNEX III 2.3.  |
| 6. DIRECTIVE 2005/61/EC           | Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events   |   |

|                                     |   |   |
|-------------------------------------|---|---|
| 7. DIRECTIVE 2005/62/EC             | Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Community standards and specifications relating to a quality system for blood establishments   | ANNEX 6.3., 6.4.                            |
| 8. DIRECTIVE 2006/17/EC             | Implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells including ANNEX I, ANNEX II  | Article 1, 4.1, ANNEX I 2.1.1., ANNEX II 1. |
| 9. DIRECTIVE 2006/86/EC             | Implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells | ANNEX II B.1.                               |
| 10. Regulation EC 1394/2007         | Advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004CHAPTER 2 MARKETING AUTHORISATION REQUIREMENTS   | Articles 2, 3, 6, 28, Annex 1               |
| 11. DIRECTIVE 2010/45/EU            | Standards of quality and safety of human organs intended for transplantation  | Article 11, 17 and Annex                    |
| 12. Commission Decision 2010/453/EU | Commission Decision of 3 August 2010 establishing guidelines concerning the conditions of inspections and control measures, and on the training and qualification of officials, in the field of human tissues and cells provided for in Directive 2004/23/EC of the European Parliament and of the Council  | All   |
| <b>GUIDELINE DOCUMENTS</b>          |   |   |
| 13. EDQM Guide                      | EDQM Guide-to-the-preparation-use-and-quality-assurance-of-blood-components-21st-edition  | 6.4.3.                                      |
| 14. EDQM Guide                      | EDQM Guide to the quality and safety of tissues and cells for human application 5th Edition   |   |
| 15. VISTART D6                      | Inspection Guidelines for EU Competent Authorities responsible for the inspection and authorisation of Blood and Tissue Establishments (VISTART D6)   | All   |

|              |  |  |
|--------------|--|--|
| 16. EudraLex | EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines | Part I, Part II, Part III (Site Master File, Q9 Quality Risk Management), Annexes (1,2,8, 14,15,17,19), Part IV. |
|--------------|--|--|

| ADDITIONAL READING (Optional)      |   | SELECTED PARTS            |
|------------------------------------|---|---------------------------|
| <b>EU LEGAL ACTS</b>               |   |                           |
| 1. Regulation EU 2017/746          | In vitro diagnostic medical devices   | Article 54 IVDR           |
| 2. Regulation EU 2017/745          | Medical devices amending Directive 2001/83/EC   | Article 59 MDR            |
| 3. DIRECTIVE 2015/565/EC           | Amending Directive 2006/86/EC as regards certain technical requirements for the coding of human tissues and cells   |                           |
| 4. DIRECTIVE 2015/566/EC           | Implementing Directive 2004/23/EC as regards the procedures for verifying the equivalent standards of quality and safety of imported tissues and cells  |                           |
| 5. Commission Decision of 3.7.2015 | Establishing a model for agreements between the Commission and relevant organisations on the provision of product codes for use in the Single European Code   |                           |
| 6. Regulation EC 726/2004          | Laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency  | Article 2.1c., 3, ANNEX I |
| 7. DIRECTIVE 2009/135/EC           | Allowing temporary derogations to certain eligibility criteria for whole blood and blood components donors laid down in Annex III to Directive 2004/33/EC in the context of a risk of shortage caused by the Influenza A(H1N1) pandemic (Text with EEA relevance) |                           |

|                               |  |   |
|-------------------------------|--|---|
| 8. DIRECTIVE<br>2011/38/EC    | Amending Annex V to Directive 2004/33/EC with regards to maximum pH values for platelets concentrates at the end of the shelf-life Text with EEA relevance | The amendments are included in the consolidated version of Dir 2005/62/EC already |
| 9. DIRECTIVE<br>2014/110/EC   | Amending directive 2004/33/EC as regards temporary deferral criteria for donors of allogeneic blood donations  | The amendments are included in the consolidated version of Dir 2005/62/EC already |
| 10. DIRECTIVE<br>2012/39/EU   | Amending Directive 2006/17/EC as regards certain technical requirements for the testing of human tissues and cells Text with EEA relevance                 | The amendments are included in the consolidated version of Dir 2005/62/EC already |
| 11. DIRECTIVE<br>2016/1214/EC | Amending Directive 2005/62/EC as regards quality system standards and specifications for blood establishments  | The amendments are included in the consolidated version of Dir 2005/62/EC already |